TherapeuticsMD, Inc.
Close on Oct 19, 2026
- Market cap
- $21.66M
- P/E (TTM)
- –
- Dividend yield
- –
About TherapeuticsMD
Pharmaceutical Preparations, SIC 2834
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company that generates revenue by out-licensing pharmaceutical products to commercial healthcare organizations. Its intellectual property portfolio centers on women's healthcare therapies, encompassing IMVEXXY for dyspareunia, BIJUVA for menopausal vasomotor symptoms, ANNOVERA for long-acting contraception, and prescription prenatal vitamin lines. The company does not conduct research, manufacturing, or direct commercial distribution. Instead, its direct customers and commercial partners are third-party pharmaceutical companies that manage the development, manufacturing, regulatory compliance, and marketing of these licensed treatments.
The company maintains corporate headquarters in Boca Raton, Florida. Its operational scale is streamlined, consisting of one full-time executive employee alongside third-party consultants who assist with administrative, legal, and financial matters. TherapeuticsMD collects royalties through three commercial licensees across several geographic markets. Product rights span the United States and its territories via Mayne Pharma, Canada through Knight Therapeutics, and Israel as well as European and other international markets through Theramex.
Summary of the business section of TherapeuticsMD's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TherapeuticsMD, Inc.
- Headquarters
- Boca Raton, FL
- Address
- 951 Yamato Road, Suite 220 33431
- Phone
- (561) 961-1900
- Employees
- 1, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Carr, Riggs & Ingram, L.L.C., Palm Beach Gardens, FL
Stock & identifiers
- Ticker
- TXMD
- Exchange
- Nasdaq
- IPO date
- May 9, 2007
- Shares outstanding
- 12M, Aug 9, 2026
- Public float
- $9.04M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, May 9, 2022; 1-for-50 reverse, May 6, 2022; 1-for-100 reverse, Oct 3, 2011; 3-for-1, Jul 27, 2009
- SEC CIK
- 25743
- CUSIP
- 88338N206
- ISIN
- US88338N2062
- LEI
- 5299004JS7RE49QHRW30
- EIN
- 87-0233535
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marlan D. Walker | Chief Executive Officer | 73,639 |
| Tommy G. Thompson | Director | 37,512 |
| Cooper C. Collins | Director | 60,516 |
| Gail K. Naughton | Director | 8,500 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Marlan Walker | $759.17K | $759.17K | $120.00K | $2 | – |
| FY2023 Marlan Walker | $1.02M | $888.91K | $684.78K | $4 | – |
| FY2022 Brian Bernick | $1.62M | $1.14M | $561.07K | $9 | – |
| FY2022 Hugh ODowd | $3.66M | $419.88K | $561.07K | $9 | – |
| FY2022 Mark Glickman | $1.43M | $975.50K | $561.07K | $9 | – |
| FY2022 Marlan Walker | $1.57M | $1.17M | $561.07K | $9 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed one full-time employee primarily engaged in an executive position.”
Corporate history
Events identified from SEC filings